{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T07:47:38Z","timestamp":1787212058973,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.rmed.2025.107979","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T11:18:09Z","timestamp":1738322289000},"page":"107979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal polyps"],"prefix":"10.1016","volume":"238","author":[{"given":"Angelica","family":"Tiotiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3923-8505","authenticated-orcid":false,"given":"Nicolas","family":"Migueres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-4784","authenticated-orcid":false,"given":"Francisco-Javier","family":"Gonzalez-Barcala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Oster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Moutard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"de Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bonniaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2025.107979_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2025.107979_bib3","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jaip.2019.02.030","article-title":"IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy","volume":"7","author":"Humbert","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.107979_bib4","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the international severe asthma registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2025.107979_bib5","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1016\/j.jaip.2021.02.059","article-title":"Cluster analysis of inflammatory biomarker expression in the international severe asthma registry","volume":"9","author":"Denton","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.107979_bib6","doi-asserted-by":"crossref","unstructured":"M. Pretolani, D. Soussan, I. Poirier, G. Thabut, M. Aubier, Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma, Eur. Respir. J. 50, 1700019. doi: 10.1183\/13993003.00019-2017.","DOI":"10.1183\/13993003.00019-2017"},{"key":"10.1016\/j.rmed.2025.107979_bib7","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2025.107979_bib8","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/all.15711","article-title":"Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both","volume":"78","author":"Pfeffer","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2025.107979_bib9","first-page":"85","article-title":"The EUFOREA pocket guide for chronic rhinosinusitis","volume":"61","author":"Hellings","year":"2023","journal-title":"Rhinology"},{"key":"10.1016\/j.rmed.2025.107979_bib10","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/all.15650","article-title":"European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis","volume":"78","author":"Gevaert","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2025.107979_bib11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaip.2016.11.007","article-title":"Identifying risk of future asthma attacks using UK medical record data: a respiratory effectiveness group initiative","volume":"5","author":"Blakey","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.107979_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12049","article-title":"Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP","volume":"11","author":"M\u00fcmmler","year":"2021","journal-title":"Clin. Transl. Allergy"},{"key":"10.1016\/j.rmed.2025.107979_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12016-022-08938-w","article-title":"Real-life effectiveness of benralizumab, mepolizumab and omalizumab in severe allergic asthma associated with nasal polyps","volume":"64","author":"Tiotiu","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.rmed.2025.107979_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.rmed.2025.107979_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2045-7022-3-3","article-title":"The skin prick test - European standards","volume":"3","author":"Heinzerling","year":"2013","journal-title":"Clin. Transl. Allergy"},{"key":"10.1016\/j.rmed.2025.107979_bib16","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.107979_bib18","first-page":"183","article-title":"Staging in rhinosinusitis","volume":"31","author":"Lund","year":"1993","journal-title":"Rhinology"},{"key":"10.1016\/j.rmed.2025.107979_bib19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/17476348.2023.2223986","article-title":"Criteria to evaluate efficacy of biologics in asthma: a Global Asthma Association survey","volume":"17","author":"Tiotiu","year":"2023","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.rmed.2025.107979_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2025.107979_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/lary.29888","article-title":"Estimating clinically meaningful change of efficacy outcomes in inadequately controlled chronic rhinosinusitis with nasal polyposis","volume":"132","author":"Han","year":"2022","journal-title":"Laryngoscope"},{"key":"10.1016\/j.rmed.2025.107979_bib22","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.107979_bib23","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/all.14235","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2025.107979_bib24","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jaip.2017.02.002","article-title":"Real-life \u00bb effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis","volume":"5","author":"Alhossan","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.107979_bib25","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.107979_bib26","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/cea.13613","article-title":"Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype","volume":"50","author":"Pelaia","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.rmed.2025.107979_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-022-01952-8","article-title":"ChAracterization of Italian severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study","volume":"23","author":"Menzella","year":"2022","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2025.107979_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107058","article-title":"Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: a real-world Dutch cohort study","volume":"206","author":"Thelen","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.107979_bib29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.107979_bib30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/JAA.S385645","article-title":"Dupilumab efficacy in patients with uncontrolled moderate-to-severe type 2 asthma regardless of perennial aeroallergen sensitization","volume":"16","author":"Corren","year":"2023","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.rmed.2025.107979_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1121237","article-title":"Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps","volume":"14","author":"Pelaia","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.rmed.2025.107979_bib32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/alr.23234","article-title":"Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: a systematic review of the current knowledge towards an attempt to compare agents' efficacy","volume":"14","author":"Papacharalampous","year":"2024","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.rmed.2025.107979_bib33","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jaip.2022.02.034","article-title":"Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis","volume":"10","author":"Cai","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.107979_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2500\/aap.2021.42.210058","article-title":"Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis","volume":"42","author":"Patel","year":"2021","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.rmed.2025.107979_bib35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.18176\/jiaci.0939","article-title":"Improvement in smell using monoclonal antibodies among patients with chronic rhinosinusitis with nasal polyps: a systematic review","volume":"33","author":"Barroso","year":"2023","journal-title":"J Investig. Allergol. Clin. Immunol."},{"key":"10.1016\/j.rmed.2025.107979_bib36","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2025.107979_bib37","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1111\/all.15772","article-title":"Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational Phase IV real-life study (DUPIREAL)","volume":"78","author":"De Corso","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2025.107979_bib38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18176\/jiaci.0391","article-title":"Effectiveness of omalizumab in severe allergic asthma and nasal polyposis: a real-life study","volume":"30","author":"Tiotiu","year":"2020","journal-title":"J Investig. Allergol. Clin. Immunol."},{"key":"10.1016\/j.rmed.2025.107979_bib39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1164\/rccm.202305-0808OC","article-title":"Association between T2-related comorbidities and effectiveness of biologics in severe asthma","volume":"209","author":"Wechsler","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.107979_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100746","article-title":"A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics","volume":"16","author":"F\u00f6rster-Ruhrmann","year":"2023","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.rmed.2025.107979_bib41","first-page":"501","article-title":"Omalizumab for the treatment of allergic rhinitis: a systematic review and meta-analysis","volume":"59","author":"Tsabouri","year":"2021","journal-title":"Rhinology"},{"key":"10.1016\/j.rmed.2025.107979_bib42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaci.2017.11.051","article-title":"Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma","volume":"142","author":"Weinstein","year":"2018","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125000411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125000411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:30:37Z","timestamp":1774427437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125000411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":40,"alternative-id":["S0954611125000411"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.107979","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal polyps","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.107979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107979"}}